ACET · Adicet Bio, Inc. · Proposed Sales
$2.93
-0.06 (-2.01%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, our outstanding and future payment obligations, and the potential need to raise additional capital to finance our future operations, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period at least twelve months from the date of issuance of these unaudited consolidated financial statements.”View the 10-Q filed Nov 5, 2026
Market Cap
$27.43M
Shares
9.36M
Volume · Nov 12
371.41K
Avg daily vol (3M)
226.86K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-04-09 | OrbiMed Genesis Master Fund, L.P. | Shareholder | 78,499 | 2026-04-09 | Themis Trading LLC |
| 2026-04-08 | OrbiMed Israel Partners II, L.P. | Shareholder | 40,416 | 2026-04-08 | Themis Trading LLC |
| 2026-04-07 | OrbiMed Israel Partners Limited Partnership | Shareholder | 64,242 | 2026-04-07 | Themis Trading LLC |
| 2024-06-05 | Kauffman Michael | Director | 5,900 | 2024-06-05 | Morgan Stanley Smith Barney LLC Executive Services |
| 2023-09-29 | CHEN SCHOR | Officer, Director | 5,500 | 2023-09-29 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Showing 1–5 of 5 filings
Key facts
CIK
1720580
CUSIP
007002207
13F (30d)
37 filings
25 filers
Visit website
Investor relations